SAN DIEGO--(BUSINESS WIRE)--n-Lorem, a nonprofit foundation, announced a new partnership with Hongene Biotech Corporation that supports n-Lorem’s efforts to discover and provide personalized experimental antisense oligonucleotide (ASO) medicines to nano-rare disease patients (1 to 30 patients worldwide) for free, for life.

圣地亚哥--（商业新闻短讯）--非营利基金会n-Lorem宣布与Hongene Biotech Corporation建立新的合作伙伴关系，支持n-Lorem努力发现并为纳米罕见病患者（全球1至30名患者）免费终身提供个性化实验反义寡核苷酸（ASO）药物。

As part of its commitment to n-Lorem and nano-rare patients, Hongene will provide amidites, compounds essential to developing ASO medicines, to n-Lorem to offset the costs of developing ASO medicines for up to 20 nano-rare patients..

作为对n-Lorem和纳米稀有患者承诺的一部分，Hongene将向n-Lorem提供酰胺，这是开发ASO药物所必需的化合物，以抵消多达20名纳米稀有患者开发ASO药物的成本。。

“In many cases, nano-rare patients will succumb to their disease without ever having hope of a treatment that will halt their progressive diseases. At n-Lorem, we can and are changing this for nano-rare patients today. Our approach enables us to discover and develop an individualized ASO medicine that targets a nano-rare patient’s unique mutation, and we do this for free, for life,” said Stanley T.

Stanley T.说：“在许多情况下，纳米级罕见患者会死于疾病，而没有希望得到阻止其进行性疾病的治疗。在n-Lorem，我们现在可以并且正在改变纳米级罕见患者的这种情况。我们的方法使我们能够发现并开发针对纳米级罕见患者独特突变的个性化ASO药物，我们可以免费终身这么做。”。

Crooke, M.D., Ph.D., Chairman, Founder, and CEO, n-Lorem Foundation. “The need from the nano-rare community is substantial and we cannot do this alone. Thanks to the generosity of Hongene, we will be able to discover and evaluate ASO medicines for nano-rare patients without having to worry about sourcing crucial amidites.

n-Lorem基金会主席、创始人兼首席执行官、医学博士克鲁克（Crooke）。“纳米稀有社区的需求是巨大的，我们无法独自做到这一点。由于Hongene的慷慨，我们将能够为纳米稀有患者发现和评估ASO药物，而不必担心寻找关键的酰胺。

At n-Lorem we are grateful for the support from our partners as together we work toward making a difference for our nano-rare patients today.”.

在n-Lorem，我们感谢我们的合作伙伴的支持，因为我们共同努力，为我们今天的纳米罕见患者做出贡献。”。

Hongene is a global specialist in nucleic acid raw material supply and CDMO services, committed to providing high-quality, high-value products with best-in-class lead times. The company reached out to n-Lorem when it learned of the foundation’s work to provide experimental ASO medicines for free to nano-rare patients who need them..

Hongene是核酸原料供应和CDMO服务的全球专家，致力于提供高质量，高价值的产品，并提供一流的交付周期。当该公司得知该基金会的工作是为需要的纳米级罕见患者免费提供实验性ASO药物时，该公司与n-Lorem取得了联系。。

“We are proud to be able to contribute to n-Lorem’s work to help people living with nano-rare illnesses. At Hongene, we are dedicated to making nucleic acid medicines universally accessible for all who need them, including patients in the non-rare disease community. We are confident that our expertise in the production and supply of these key raw materials will be a tremendous asset that will help further the foundation’s mission to bring ASO medicines to those who need them most,” said Wei Jiang, Founder and Chief Executive Officer at Hongene..

“我们很自豪能够为n-Lorem帮助纳米罕见病患者的工作做出贡献。在Hongene，我们致力于使所有需要核酸药物的人，包括非罕见病社区的患者，都能普遍获得核酸药物。我们相信，我们在生产和供应这些关键原材料方面的专业知识将是一笔巨大的资产，将有助于进一步推动基金会的使命，将ASO药物带给最需要的人，”Hongene创始人兼首席执行官Wei Jiang说道。。

About Hongene

关于Hongene

Hongene is an end-to-end partner for specialist nucleic acid manufacturing, offering a wide range of products to meet the needs of the life sciences industry. From standard raw material building blocks to complex oligonucleotides and mRNA, Hongene consistently delivers with exceptional quality and value.

Hongene是专业核酸制造的端到端合作伙伴，提供多种产品以满足生命科学行业的需求。从标准的原材料构建块到复杂的寡核苷酸和mRNA，Hongene始终以卓越的质量和价值提供产品。

Through collaborations Hongene can help unlock the full potential of nucleic acids to develop life-changing treatments for patients worldwide..

通过合作，Hongene可以帮助释放核酸的全部潜力，为全球患者开发改变生命的治疗方法。。

For more information about Hongene and its range of nucleic acid products, visit the website at www.hongene.com and follow us on Linkedin.

有关Hongene及其核酸产品系列的更多信息，请访问网站www.Hongene.com，并在Linkedin上关注我们。

About n-Lorem

关于n-Lorem

n-Lorem Foundation is a non-profit organization established to apply the efficiency, versatility, and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat nano-rare patients diagnosed with diseases that are the result of a single genetic defect unique to only one or very few individuals.

n-Lorem基金会是一个非营利性组织，旨在应用反义技术的效率，多功能性和特异性，慈善地提供实验性反义寡核苷酸（ASO）药物，以治疗被诊断为疾病的纳米罕见患者，这些疾病是由一个单一的遗传缺陷引起的，只有一个或很少的人。

Nano-rare patients describe a very small group of patients (1-30 worldwide) who, because of their small numbers, have few if any treatment options. n-Lorem Foundation was created to provide hope to these nano-rare patients by developing individualized ASO medicines, which are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality.

纳米罕见患者描述了一小部分患者（全世界1-30名），由于人数少，几乎没有治疗选择。创建n-Lorem基金会是为了通过开发个性化的ASO药物为这些纳米罕见患者提供希望，ASO药物是短链的修饰DNA，可以特异性靶向缺陷基因的转录本以纠正异常。

The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. To date, n-Lorem received over 260 applications for treatment with more than 120 nano-rare patients approved. n-Lorem was founded by Stanley T. Crooke, M.D., Ph.D., former chairman and CEO of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics.

实验性ASO药物的优点是它们可以快速，廉价且高度特异性地开发。迄今为止，n-Lorem收到了260多份治疗申请，批准了120多名纳米罕见患者。n-Lorem由医学博士斯坦利·克鲁克（Stanley T.Crooke）创建，他是Ionis Pharmaceuticals的前董事长兼首席执行官，于1989年创建了Ionis Pharmaceuticals，并通过他的远见和领导力，将该公司确立为RNA靶向治疗的领导者。

Follow us on Twitter, Facebook, LinkedIn and YouTube..

在Twitter、Facebook、LinkedIn和YouTube上关注我们。。

To learn more about n-Lorem’s mission at www.nlorem.org, and please consider giving to n-Lorem to bring hope, possibility and treatment options to these patients and families in need.

要了解更多有关n-Lorem使命的信息，请访问www.nlorem.org，并考虑向n-Lorem捐款，为这些有需要的患者和家庭带来希望、可能性和治疗选择。